Chimeric antigen receptor T-cell therapy after COVID-19 in refractory high-grade B-cell lymphoma
Description
Although chimeric antigen receptor T-cell (CAR-T) therapies have dramatically improved the outcomes of relapsed/refractory B-cell malignancies, recipients suffer from severe humoral immunodeficiencies. Furthermore, patients with coronavirus disease
